// App-Quantinova.ai

888 : Inactivation of the DLC1 RhoGAP tumor suppressor by point mutation occurs commonly in human cancer and can result from Rho-dependent or Rho-independent mechanisms

Researchers

Presenter

  • Xiaolan Qian

Principal Investigators

  • Dunrui Wang

  • Beatriz Sanchez-Solana

  • Brajendra K. Tripathi

  • Marian E. Durkin

  • Alex Papageorge

  • Douglas R. Lowy

Medical Centers

  • National Cancer Institute, Bethesda, MD

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Genetic Disorder

  • Musculoskeletal

Disease

  • Lung Cancer

  • Colorectal Cancer

  • Gastric Cancer

  • Melanoma

  • Solid malignancies

  • Short stature, onychodysplasia, facial dysmorphism, and hypotrichosis

Biomarkers

  • DNA methylation

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved